Market Closed -
Hong Kong S.E.
01:38:22 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.78
HKD
|
0.00%
|
|
+7.88%
|
-50.42%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
-
|
1,150
|
1,359
|
669.9
|
-
|
-
|
Enterprise Value (EV)
1 |
-
|
665.7
|
1,173
|
892.3
|
214.5
|
689.9
|
P/E ratio
|
-
|
-2.91
x
|
-2.86
x
|
-2.17
x
|
-1.5
x
|
-1.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
11.3
x
|
25.2
x
|
4.15
x
|
3.8
x
|
8.78
x
|
EV / Revenue
|
-
|
6.53
x
|
21.8
x
|
5.53
x
|
1.22
x
|
9.04
x
|
EV / EBITDA
|
-
|
-1.67
x
|
-2.65
x
|
-3.2
x
|
-0.58
x
|
-1.5
x
|
EV / FCF
|
-
|
-2.09
x
|
-
|
-0.93
x
|
-0.39
x
|
-1.74
x
|
FCF Yield
|
-
|
-47.8%
|
-
|
-108%
|
-255%
|
-57.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
-
|
4,19,920
|
4,16,576
|
4,06,579
|
-
|
-
|
Reference price
2 |
7.496
|
2.738
|
3.263
|
1.648
|
1.648
|
1.648
|
Announcement Date
|
21/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
50.24
|
101.9
|
53.85
|
161.4
|
176.3
|
76.29
|
EBITDA
1 |
-434.4
|
-398.5
|
-442.1
|
-278.9
|
-369.2
|
-459.8
|
EBIT
1 |
-480.2
|
-442.3
|
-485
|
-323.7
|
-455.3
|
-437.6
|
Operating Margin
|
-955.81%
|
-434.13%
|
-900.75%
|
-200.54%
|
-258.3%
|
-573.63%
|
Earnings before Tax (EBT)
1 |
-
|
-407
|
-462.8
|
-308.6
|
-457.4
|
-437.8
|
Net income
1 |
-
|
-406.7
|
-462.6
|
-308.6
|
-457.4
|
-480.5
|
Net margin
|
-
|
-399.19%
|
-859.01%
|
-191.18%
|
-259.5%
|
-629.82%
|
EPS
2 |
-
|
-0.9400
|
-1.140
|
-0.7600
|
-1.095
|
-1.180
|
Free Cash Flow
1 |
-
|
-318
|
-
|
-964
|
-547
|
-396
|
FCF margin
|
-
|
-312.09%
|
-
|
-597.15%
|
-310.32%
|
-519.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
23.56
|
-
|
80.13
|
36.08
|
17.76
|
26.66
|
134.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-275.6
|
-
|
-216.2
|
-255.8
|
-229.3
|
-196.7
|
-127.1
|
Operating Margin
|
-1,170.02%
|
-
|
-269.8%
|
-708.85%
|
-1,290.54%
|
-737.89%
|
-94.27%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-204.1
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.4700
|
-
|
-0.5800
|
-0.5600
|
-0.4600
|
-0.2900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/22
|
29/08/22
|
30/03/23
|
22/08/23
|
27/03/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
222
|
-
|
19.9
|
Net Cash position
1 |
857
|
484
|
186
|
-
|
455
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.7972
x
|
-
|
-0.0434
x
|
Free Cash Flow
1 |
-
|
-318
|
-
|
-964
|
-547
|
-396
|
ROE (net income / shareholders' equity)
|
-
|
-23.7%
|
-35%
|
-822%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-17.4%
|
-32.1%
|
-15.8%
|
-9.4%
|
-
|
Assets
1 |
-
|
2,340
|
1,440
|
1,953
|
4,866
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
22.2
|
-
|
426
|
80
|
80
|
Capex / Sales
|
-
|
21.77%
|
-
|
263.88%
|
45.38%
|
104.86%
|
Announcement Date
|
21/03/22
|
30/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
1.648
CNY Average target price
7.58
CNY Spread / Average Target +360.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -50.42% | 92.45M | | +25.83% | 661B | | +27.09% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +14.05% | 231B | | +4.97% | 200B | | -9.37% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|